The global landscape for treating liquid tumors is undergoing a seismic shift as genomic profiling becomes the gold standard for clinical intervention. In 2026, the medical community has moved decisively away from broad-spectrum chemotherapy toward precision medicine that targets specific molecular mutations. This transition is not only improving patient survival rates but also reshaping how...